3 Reasons to Buy Moderna Stock

In mid-June 2021, Moderna stock began a steady rally from $196 to more than $500. In the last few months, the company has reported early positive data from its phase 1 trial and has increased its forecast for its total revenue by 2022. This is an excellent time to buy Moderna stock. Here are some reasons to do so:

First, Moderna has a great track record. Moderna’s vaccine project was funded in part by the U.S. government through Operation Warp Speed. It’s now valued at more than $25 billion, and Moderna’s executives have reaped millions in stock since the vaccine was first announced. The company’s stock price could skyrocket if the vaccine becomes a success. But that doesn’t mean investors should rush to buy Moderna stock.

Next, Moderna is working on other vaccines and cancer drugs. It recently struck a deal with privately held Carisma Therapeutics to incorporate its delivery system with their white blood cell technology. In addition, Moderna is banking on the power of messenger RNA to deliver the instructions to create a protein. This technology may be the key to a successful future for Moderna. Moderna’s investors should consider investing in this stock. But before investing in Moderna stock, consider how it might impact its future.

First, investors should be aware of Moderna’s history. Moderna stock is up by about 20% over the past week, which outperformed the S&P 500. Second, the stock may benefit from an additional boost in demand for Covid-19 shots. In addition, Moderna’s pipeline includes over 20 vaccines and therapeutic candidates. If Moderna can successfully get this approval, it could have a large market share of the Covid vaccine.

Back to top button